eli lilly retatrutide trials New Phase 3 data just dropped 👀 Lilly's trial reported average weight loss approaching 30%, with some patients achieving results historically associated with bariatric surgery. A few important caveats Retatrutide, the next generation of

LY3437943 (retatrutide), a triple agonist at GIP, GLP-1, and glucagon receptors

Overview GLP-1 injections have garnered attention as a promising treatment for obesity

If youre considering semaglutide, or wondering how long you should continue, the team at PRIME Medicine in Corona Del Mar, CA can help you create a personalized plan that fits your goals and supports lasting success

[DOI] [PMC free article] [PubMed] [Google Scholar] 61.Bossart M, Wagner M, Elvert R, Evers A, Hubschle T, Kloeckener T, et al

DOI: 10.1016/j.cmet.2019.12.012 View Source Nature 2022 The molecular basis of GLP-1R / GIPR co-agonism for weight management Nauck MA, D'Alessio DA PMID: 35948706 View Source For Research Use Only Important Notice This product is sold strictly for research, laboratory, and educational purposes only